Kura Oncology Inc Revenue Growth Rates (KURA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kura Oncology Inc   (NASDAQ: KURA)
 

KURA's Revenue Growth by Quarter and Year

Kura Oncology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KURA/growth
https://api.csimarket.com/api/v1/companies/KURA/fundamentals
https://api.csimarket.com/api/v1/companies/KURA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KURA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 22.84
2nd Quarter June 20.87
1st Quarter March 18.27
FY 61.98





KURA Revenue third quarter 2026 Y/Y Growth Comment
Kura Oncology Inc reported Revenue increase of 10.07% year on year in the third quarter 2026, to $ 22.84 millions, this is lower than Kura Oncology Inc 's recent average Revenue improvement of 23.12%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue growth. While Kura Oncology Inc ' s Revenue growth of 10.07% ranks overall at the positon no. 618 in the third quarter 2026.


KURA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.07 %
2nd Quarter June 36.49 %
1st Quarter March 29.48 %
FY   -

Financial Statements
Kura Oncology Inc 's third quarter 2026 Revenue $ 22.84 millions KURA's Income Statement
Kura Oncology Inc 's third quarter 2025 Revenue $ 20.75 millions Quarterly KURA's Income Statement


KURA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.43 %
2nd Quarter June 14.23 %
1st Quarter March 5.36 %
FY (Year on Year)   -


Back to KURA Growth rate Comparisons >> Back to KURA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #146
Overall #618

Revenue Y/Y Growth Statistics
High Average Low
463.64 % 23.12 % -100 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #146
Overall #618
Revenue Y/Y Growth Statistics
High Average Low
463.64 % 23.12 % -100 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Kura Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
72.73 % -5 % -100 %
(Sep 30 2015)  


KURA's III. Quarter Q/Q Revenue Comment
Kura Oncology Inc achieved in the III. Quarter 2026 above company average sequential Revenue increase of 9.43%, to $ 22.84 millions, from $20.87 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Kura Oncology Inc 's Revenue growth quarter on quarter, overall rank is 650.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #650
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #650
Revenue Q/Q Growth Statistics
High Average Low
72.73 % -5 % -100 %
(Sep 30 2015)  


KURA's III. Quarter Q/Q Revenue Comment
Kura Oncology Inc achieved in the III. Quarter 2026 above company average sequential Revenue increase of 9.43%, to $ 22.84 millions, from $20.87 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Kura Oncology Inc 's Revenue growth quarter on quarter, overall rank is 650.


Kura Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 79.31
Y / Y Revenue Growth (TTM) -23.76 %
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 2.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 3490


Cumulative Revenue growth Comment
Kura Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Kura Oncology Inc 's annual Revenue improvement would be -23.76% year on year to $79 millions.

In the Healthcare sector 461 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 153
Healthcare Sector # 462
Overall # 3481

Revenue TTM Y/Y Growth Statistics
High Average Low
-23.76 %
 -23.76 %
-23.76 %
(Sep 30 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 158
Sector # 475
S&P 500 # 3490
Cumulative Revenue growth Comment
Kura Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Kura Oncology Inc 's annual Revenue fall would be -23.76% year on year to $79 millions.

In the Healthcare sector 461 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 153
Healthcare Sector # 462
Overall # 3481

Revenue TTM Y/Y Growth Statistics
High Average Low
-23.76 %
-23.76 %
-23.76 %
(Sep 30 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 158
Sector # 475
S&P 500 # 3490




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KURA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions


About Kura Oncology Inc Revenue Growth Rates (KURA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kura Oncology Inc (CIK 1422143).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-455455
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kura Oncology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.